Boston Family Office’s Pfizer PFE Stock Holding History

Boston Family Office’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Sell	53,337 -200	-0.4%	-$5.23K	0.08%	161
2026 Q1	$1.5M	Sell	53,537 -8,827	-14%	-$235K	0.1%	148
2025 Q4	$1.55M	Sell	62,364 -4,011	-6%	-$101K	0.1%	142
2025 Q3	$1.69M	Sell	66,375 -272	-0.4%	-$6.71K	0.11%	135
2025 Q2	$1.62M	Sell	66,647 -695	-1%	-$16.2K	0.11%	132
2025 Q1	$1.71M	Sell	67,342 -503	-0.7%	-$13.2K	0.12%	124
2024 Q4	$1.8M	Buy	67,845 +1,563	+2%	+$42.4K	0.12%	119
2024 Q3	$1.92M	Sell	66,282 -3,243	-5%	-$94.6K	0.13%	116
2024 Q2	$1.95M	Buy	69,525 +1,154	+2%	+$31.8K	0.14%	111
2024 Q1	$1.9M	Sell	68,371 -652	-0.9%	-$18.1K	0.14%	114
2023 Q4	$1.99M	Sell	69,023 -1,159	-2%	-$35K	0.15%	114
2023 Q3	$2.33M	Buy	70,182 +450	+0.6%	+$15.9K	0.19%	95
2023 Q2	$2.56M	Sell	69,732 -280	-0.4%	-$10.9K	0.2%	95
2023 Q1	$2.86M	Sell	70,012 -495	-0.7%	-$21.4K	0.23%	84
2022 Q4	$3.61M	Sell	70,507 -1,892	-3%	-$90.7K	0.3%	76
2022 Q3	$3.17M	Sell	72,399 -879	-1%	-$42.7K	0.28%	77
2022 Q2	$3.84M	Sell	73,278 -350	-0.5%	-$17.8K	0.32%	72
2022 Q1	$3.81M	Buy	73,628 +1,915	+3%	+$99.4K	0.27%	79
2021 Q4	$4.24M	Sell	71,713 -858	-1%	-$42.5K	0.28%	77
2021 Q3	$3.12M	Sell	72,571 -82	-0.1%	-$3.63K	0.23%	91
2021 Q2	$2.85M	Sell	72,653 -11,136	-13%	-$433K	0.2%	101
2021 Q1	$3.02M	Buy	83,789 +949	+1%	+$33.7K	0.23%	94
2020 Q4	$3.05M	Sell	82,840 -6,816	-8%	-$250K	0.23%	92
2020 Q3	$3.12M	Sell	89,656 -1,259	-1%	-$44.1K	0.28%	78
2020 Q2	$2.82M	Sell	90,915 -3,451	-4%	-$117K	0.27%	84
2020 Q1	$2.92M	Sell	94,366 -11,523	-11%	-$393K	0.35%	73
2019 Q4	$3.94M	Sell	105,889 -12,522	-11%	-$446K	0.37%	75
2019 Q3	$4.04M	Buy	118,411 +57	+0%	+$2.07K	0.42%	70
2019 Q2	$4.86M	Sell	118,354 -59	-0%	-$2.34K	0.51%	59
2019 Q1	$4.77M	Sell	118,413 -276	-0.2%	-$11.1K	0.52%	57
2018 Q4	$4.92M	Sell	118,689 -1,446	-1%	-$60K	0.61%	51
2018 Q3	$5.02M	Buy	120,135 +671	+0.6%	+$25.8K	0.53%	58
2018 Q2	$4.11M	Sell	119,464 -105	-0.1%	-$3.59K	0.47%	69
2018 Q1	$4.03M	Sell	119,569 -211	-0.2%	-$7.25K	0.46%	71
2017 Q4	$4.12M	Sell	119,780 -9,575	-7%	-$326K	0.45%	71
2017 Q3	$4.38M	Buy	129,355 +57	+0%	+$1.83K	0.5%	67
2017 Q2	$4.12M	Buy	129,298 +305	+0.2%	+$9.62K	0.49%	68
2017 Q1	$4.19M	Sell	128,993 -25,891	-17%	-$816K	0.51%	65
2016 Q4	$4.77M	Sell	154,884 -217	-0.1%	-$6.63K	0.62%	52
2016 Q3	$4.98M	Sell	155,101 -429	-0.3%	-$14.3K	0.65%	50
2016 Q2	$5.2M	Sell	155,530 -2,434	-2%	-$77.7K	0.67%	46
2016 Q1	$4.44M	Buy	157,964 +18,432	+13%	+$526K	0.59%	54
2015 Q4	$4.27M	Buy	139,532 +823	+0.6%	+$25.9K	0.58%	58
2015 Q3	$4.13M	Sell	138,709 -3,162	-2%	-$101K	0.58%	57
2015 Q2	$4.51M	Buy	141,871 +2,339	+2%	+$76.2K	0.57%	60
2015 Q1	$4.61M	Sell	139,532 -210	-0.2%	-$6.68K	0.57%	57
2014 Q4	$4.13M	Sell	139,742 -8,850	-6%	-$254K	0.51%	67
2014 Q3	$4.17M	Sell	148,592 -2,010	-1%	-$56.4K	0.54%	63
2014 Q2	$4.24M	Buy	150,602 +4,778	+3%	+$136K	0.54%	61
2014 Q1	$4.44M	Sell	145,824 -2,834	-2%	-$84.5K	0.59%	54
2013 Q4	$4.32M	Sell	148,658 -2,114	-1%	-$61.5K	0.57%	58
2013 Q3	$4.11M	Sell	150,772 -3,466	-2%	-$94.3K	0.58%	56
2013 Q2	$4.1M	Buy	+154,238	New	+$4.26M	0.62%	52

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Boston Family Office's PFE Position: Q2 2026 in Review

Boston Family Office reduced its Pfizer (PFE) stake by 0.37% in Q2 2026, selling an estimated $5.23K and leaving 53,337 shares worth $1.28M. The position accounts for 0.08% of the portfolio, ranked #161.

Boston Family Office first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.2M in Q2 2016. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Boston Family Office held 53,337 shares of Pfizer worth $1.28M as of Q2 2026.
Boston Family Office sold 200 Pfizer shares in Q2 2026, an estimated $5.23K.
Pfizer made up 0.08% of Boston Family Office's portfolio in Q2 2026, its #161 holding.
Boston Family Office first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Boston Family Office's Pfizer position peaked at $5.2M in Q2 2016.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Boston Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.